The NY-ESO-1/TCR sequence was mutated for high affinity with replacements of G50A and A51E in CDR2 region. This is a first-in-human clinical trial of the novel NY-ESO-1-specfic TCR-T cell transfer to evaluate the safety, in vivo cell kinetics and clinical responses. It was designed...
本发明涉及NY‑ESO‑1特异的TCR及其制备方法,用人工果蝇抗原提呈细胞负载NY‑ESO‑1抗原肽,激活CD8+T细胞产生CTL细胞,产生的细胞毒性CTL细胞经流式分选仪用HLA‑A*02:01NY‑ESO‑1Tetramer‑SLLMWITQC‑APC(MBL,TS‑M011‑2)及CD8‑FITC荧光双染、进行流式检测,筛选收集双阳性的CTL细胞,将分...
激活cd8+t细胞产生细胞毒性t淋巴细胞(cytotoxiclymphocyte,ctl),产生的ctl经流式分选仪分选,得到高表达hla-a*02:01ny-eso-1(sllmwitqc)tetramer的ctl细胞,进一步进行单细胞tcr基因测序(可变区),将tcr基因进行优化及设计,转入293t细胞检测tcr的表达情况。
参见例如,Kabat,“免疫学蛋白质序列(Sequences of Proteins of Immunological Interest)”,国立卫生研究院(National Institutes of Health),贝 塞斯达,马里兰州,(1991);Al‑Lazikani等人,《分子生物学期刊(J.Mol.Biol.)》273:927‑ 948(1997);和Martin等人,《美国科学院院报》86:9268‑9272(1989)。公共数据...
嵌合抗原受体(car)将t细胞特异性重定向到在癌细胞表面表达的抗体识别抗原,而t细胞受体(tcr)将靶标范围扩大到包括细胞内肿瘤抗原。对b细胞分化抗原cd19具有特异性的car重定向t细胞在治疗b细胞恶性肿瘤中显示出显著疗效,而tcr重定向t细胞在患有实体癌的患者中显示出益处。stauss等人描述了修饰治疗性car和tcr的策略,用于...
The vector RNA copy number was calculated in reference to a standard curve comprised of linearized plasmid DNA containing the target sequences, diluted over a 7-log range (1 × 107 to 1 × 101 copies). The genome titer used throughout the experiments reflects the number of physical...
NY-ESO-1 SPECIFIC TCRS AND METHODS OF USE THEREOFThe present disclosure relates to NY-ESO-1 specific TCR amino acid sequences and methods of their use.LU HailingTER MEULEN Jan Henrik
NY-ESO-1 specific TCRs and methods of use thereofThe present disclosure relates to NY-ESO-1 specific TCR amino acid sequences and methods of their use.Lu HailingTer Meulen Jan Henrik
Initial response rates to therapy were low, suggesting the need to improve the function of TCR-transduced PBL. We constructed standard bicistronic retroviral vectors using an internal promoter or internal ribosomal entry site element as well as vectors incorporating coding sequences for 2A linker ...
Results Through immuno-exclusive HLA-A02/RenMab mice, combined with high-throughput Beacon screening and sequence verification, fully humanized antibody sequences of NY-ESO-1/HLA-A02 with mature affinity in vivo were obtained. The obtained antibody affinity is at the nM level (TCR is generally at...